Development of a scalable process for the PPAR-
alpha agonist GW641597X incorporating Baeyer-
Villiger Chemistry and retrospective ICH M7 
assessment

Thierry Boyer, b Bernie M. Choudary, a Andrew J. Edwards, c Erika Etridge, a Steve Etridge, a
Amanda Giddings, d Jim Harvey, d Neil S. Hodnett, a,c Sophie Druot-Houllemare, a John H.
Leahy, c Kathryn Payne, a Robert Reid, a,c Andrew D. Roberts, c Mike Sasse, a Alec Simpson, c
Steve Smith, a Neil G. Stevenson, c Paul Stonestreet, a Michael William Urquhart, a,c,* Angela
White. d

a Formerly from: Chemical Development, GlaxoSmithKline Pharmaceuticals, Old Powders
Mills, Nr. Leigh, Tonbridge, Kent, TN11 9AN, United Kingdom.
b Formerly from: GlaxoSmithKline Research Centre, 25-27 Avenue du Quebec, 91951 Les
Ulis, France.
c GlaxoSmithKline, Research and Development, Medicines Research Centre, Gunnels Wood
Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
d GlaxoSmithKline, David Jack Centre for Research and Development, Park Road, Ware,
Hertfordshire, SG12 0DP, United Kingdom

* To whom correspondence should be addressed (Michael.W.Urquhart@gsk.com.)
Supporting Information

Table of Contents

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$^1$H and $^{13}$C NMR spectra for GW641597X</td>
<td>S-3 to S-4</td>
</tr>
<tr>
<td>2</td>
<td>CID Mass Spectrum for GW641597X</td>
<td>S-5</td>
</tr>
<tr>
<td>3</td>
<td>$^1$H NMR spectra for compounds</td>
<td>S-6 to S-20</td>
</tr>
</tbody>
</table>
1. $^1$H NMR spectra for GW641597X
2. $^{13}$C NMR spectra for GW641597X

![NMR Spectra Image]

**1**
3. CID Mass Spectrum for GW641597X
$^1$H NMR spectra for compounds

![NMR Spectrum Image]
20